<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253212</url>
  </required_header>
  <id_info>
    <org_study_id>P120905</org_study_id>
    <secondary_id>2014-000393-19</secondary_id>
    <nct_id>NCT02253212</nct_id>
  </id_info>
  <brief_title>Safety of BBB Opening With the SonoCloud</brief_title>
  <acronym>SONOCLOUD</acronym>
  <official_title>A Study to Evaluate the Safety of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SonoCloud Implantable Device in Patients With Recurrent Glioblastoma Before Chemotherapy Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PURPOSE: The purpose of this study is to determine whether transient opening of the&#xD;
      blood-brain barrier by pulsed ultrasound using the SonoCloud implantable ultrasound device is&#xD;
      safely tolerated in patients with recurrent glioblastoma immediately before systemic delivery&#xD;
      of carboplatin-based chemotherapy.&#xD;
&#xD;
      STUDY HYPOTHESIS: The blood-brain barrier can be safely opened using pulsed ultrasound prior&#xD;
      to chemotherapy administration in patients with recurrent glioblastoma. Transient opening of&#xD;
      the blood-brain barrier by pulsed ultrasound will increase the glioblastoma exposure to&#xD;
      carboplatin-based chemotherapy and increase progression-free and overall survival in patients&#xD;
      with recurrent glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with recurrent malignant gliomas, who have already been treated by a combination&#xD;
      of surgery, radiation therapy and/or chemotherapy, few treatment options currently exist.&#xD;
      Salvage therapies typically consist of systemic administration of chemotherapy agents, which&#xD;
      have been shown to have limited effectiveness as median survival in this patient group is&#xD;
      currently only 6 months.&#xD;
&#xD;
      One limitation to the efficacy of systemic chemotherapy in the treatment of brain tumors is&#xD;
      the blood-brain barrier (BBB). To enhance the delivery of systemically administered&#xD;
      chemotherapy agents to brain tumors, an implantable ultrasound device was developed that can&#xD;
      be used to temporarily disrupt the BBB. Delivery of pulsed ultrasound, in combination with an&#xD;
      ultrasound contrast agent, has been shown to temporarily disrupt the BBB for a duration of&#xD;
      more than 6 hours and allow for a significantly increased penetration of systemically&#xD;
      administered chemotherapy drugs in pre-clinical studies.&#xD;
&#xD;
      This study will evaluate the safety of temporary disruption of the BBB during carboplatin&#xD;
      chemotherapy delivery in patients with recurrent glioblastoma. This study will also evaluate&#xD;
      the maximum tolerated dose of ultrasound that can be used to disrupt the BBB.&#xD;
&#xD;
      The use of dynamic contrast-enhanced MRI will be evaluated for determining the extent and&#xD;
      magnitude of BBB opening. Clinical efficacy (Survival) and radiological efficacy (Progression&#xD;
      Free Survival) will also be evaluated as secondary endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of transient disruption of the blood-brain barrier using the SonoCloud system in patients with recurrent glioblastoma.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose of ultrasound with the SonoCloud system for transient disruption of the BBB.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the disruption of the BBB by the SonoCloud system using dynamic T1 contrast-enhanced MRI.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Glioma</condition>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>SonoCloud + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SonoCloud</intervention_name>
    <description>SonoCloud : dose escalation</description>
    <arm_group_label>SonoCloud + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC</description>
    <arm_group_label>SonoCloud + carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age greater than 18 years.&#xD;
&#xD;
          -  Subjects with recurrent glioma who have failed standard therapy with surgery and/or&#xD;
             treatment with radiation and temozolomide.&#xD;
&#xD;
          -  Patient eligible for Carboplatin-based chemotherapy&#xD;
&#xD;
          -  Contrast-enhanced tumor less than 35 mm in diameter&#xD;
&#xD;
          -  No risk of cerebral herniation&#xD;
&#xD;
          -  Able to tolerate pre/post procedure steroid treatment&#xD;
&#xD;
          -  Social security affiliated (in France)&#xD;
&#xD;
          -  Able and willing to give signed and informed consent&#xD;
&#xD;
          -  Normal biological status&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dl&#xD;
&#xD;
          -  Platelets ≥ 100000/mm3&#xD;
&#xD;
          -  Neutrophils ≥ 1500/mm3&#xD;
&#xD;
          -  Normal creatine clearance ≥ 60ml/mn&#xD;
&#xD;
          -  ASAT &lt; 3 N&#xD;
&#xD;
          -  ALAT &lt; 3 N&#xD;
&#xD;
          -  Normal Bilirubin Level &lt; 1.5 N&#xD;
&#xD;
          -  Alkaline Phosphatase &lt; 3 N&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
          -  Prothrombin Level ≥ 70%&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Allergic to Iodine, Gadolinium, Xylocain&#xD;
&#xD;
          -  Contra-indications to echographic contrast agent (microbubbles)&#xD;
&#xD;
          -  Severe Renal insufficiency&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Possible toxic treatment for CNS&#xD;
&#xD;
          -  Previously infected surgical field&#xD;
&#xD;
          -  Uncontrolled epilepsy&#xD;
&#xD;
          -  MRI contra-indications&#xD;
&#xD;
          -  Hemostasis troubles thrombopenia &lt;75.000, TP &lt;60%, INR &gt;1.5, anti-platelet or&#xD;
             anticoagulant therapy on-going)&#xD;
&#xD;
          -  Active phlebitis or active pulmonary embolism&#xD;
&#xD;
          -  Pregnant or currently breast-feeding&#xD;
&#xD;
          -  Patients under judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Idbaih, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpetriere - Neurosurgery Department</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood brain barrier (BBB)</keyword>
  <keyword>Disruption</keyword>
  <keyword>Low intensity pulsed ultrasound (LIPU)</keyword>
  <keyword>Sonocloud device</keyword>
  <keyword>Glioblastoma (GBM)</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Therapeutic Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

